載入中
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
前收盤價
US$26.25
−US$0.18 · -0.68%
盤前
US$26.24
−US$0.01 · -0.04%
10月8日 上午4:44 ET
盤中時間採用ET。市場資料可能有所延遲。
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
日內區間
目前US$26.25
52週區間
目前US$26.25
盤中時間採用ET。市場資料可能有所延遲。
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
日內區間
目前US$26.25
52週區間
目前US$26.25
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 |
|---|---|---|---|---|
| 營收 | — | 1.68億 USD | — | — |
| 銷貨成本 | 240.3萬 USD | — | — | — |
| 毛利 | −240.3萬 USD | 1.68億 USD | — | — |
| 研究與開發 | 1.08億 USD | 8349.6萬 USD | 7394.5萬 USD | 8819.2萬 USD |
| 銷售、一般及管理費用 | 3445.1萬 USD | 2641.8萬 USD | 2460.6萬 USD | 2283.4萬 USD |
| 營業費用 | 1.4億 USD | 1.1億 USD | 9855.1萬 USD | 1.11億 USD |
| 利息收入 | 1177.9萬 USD | 465.4萬 USD | 196.6萬 USD | 202.8萬 USD |
| 折舊和攤銷 | 240.3萬 USD | 329.7萬 USD | 408.9萬 USD | 382萬 USD |
| 營業利益 | −1.43億 USD | 5758.6萬 USD | −9855.1萬 USD | −1.11億 USD |
| 淨利 | −1.31億 USD | 5223.1萬 USD | −1億 USD | −1.15億 USD |
公司資料更新於 2026年10月8日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$64.00
上漲空間 143.81%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI3751.66萬0.00%2.3兆 USD0.03%US$381.03-0.40%
iShares Russell 2000 ETFIWM2435.24萬0.03%785.63億 USD0.19%US$277.7-1.29%
State Street SPDR S&P Pharmaceuticals ETFXPH958.93萬1.97%4.62億 USD0.35%US$62.910.00%
Vanguard Extended Market ETFVXF875.11萬0.01%954億 USD0.05%US$233.49-1.56%
iShares Russell 2000 Growth ETFIWO737.13萬0.05%142.49億 USD0.24%US$355.37-1.43%
iShares Biotechnology ETFIBB685.08萬0.07%104.01億 USD0.44%US$203.34+0.12%
Vanguard Russell 2000 ETFVTWO538.74萬0.03%180億 USD0.06%US$112.21-1.26%
Schwab U.S. Small-Cap ETFSCHA509.08萬0.02%220.14億 USD0.03%US$32.61-1.47%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Pharmaceuticals ETFXPHVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
